Propel Careers Networking and Panel Discussion
This is the fourth event in a series of events that Propel Careers is hosting in 2010 to enhance connections between life sciences companies, graduate students (MBA, Ph.D., MD, MS) and post doctoral fellows. Together, we can help to foster future life sciences leaders and strengthen our industry through the connections made.
Career Paths in Diagnostic and Personalized Medicine Life Sciences Companies
The panel will include speakers from the following companies:
Daniel W. Paterson, Chief Operating Officer, On-q-ity
Harry Glorikian, Founder and Managing Partner, Scientia Advisors
Corey Braastad, Ph.D., Manager of Operations, Athena Diagnostics
Thomas Neyarapally, Senior Vice President, Corporate Development, Gene Network Sciences
Moderator: Christopher Tsai, MD, MPH, Director of Clinical Informatics, Generation
Health; Co-Founder, careinnovators
Date: March 25nd, 2010
Location: Cooley Godward Kronish LLP
500 Boylston Street, 14th Floor, Boston, MA 02116
Time: 5:30pm – 8:00pm
(Check in starts at 5:30pm, panel starts as 6:15pm)
Registration Details: http://propelcareers4.eventbrite.com
If you are a MA-based student interested in attending this event, financial assistance is available through the Stay in MA program. Please visit www.stayinma.com
This panel will feature life sciences leaders from Boston area companies involved in diagnostics and personalized medicine. The panelists will share their experiences and insights into their career paths, lessons learned, and emerging industry trends for students to consider as they contemplate their future careers. Join us for a night of networking among companies and fellow students to build your connections in the life sciences industry. Refreshments and light fare will be provided.
Propel Careers Panel Speakers Biographies
Moderator: Christopher Tsai, MD, MPH, Director of Clinical Informatics, Generation Health; Co-Founder, careinnovators
Christopher Tsai is currently the Director of Clinical Informatics at Generation Health, a genetic testing pharmacy benefits management start-up located in Waltham, MA. He oversees the core analytics platform and various informatics initiatives. He is also the Co-Founder of careinnovators, a website designed for the health care entrepreneurial community. In addition to the site’s free industry databases, careinnovators profiles interesting health care startups and the news that affects them. Before Generation Health, Dr. Tsai privately consulted on business strategy and product design for health IT start-ups and a major global telecom. Prior to that, he worked at Outcome Sciences, a patient registry firm, as the Director of Medical Informatics/Associate Medical Director. He led the international case acquisition for the Avian/Pandemic Flu Registry and helped launch its Physician Quality Reporting Initiative product. Dr. Tsai completed his biomedical informatics fellowship at Brigham & Women’s Hospital with the Harvard-MIT Division of Health Sciences and Technology. He served as chief resident at U.C. San Diego’s preventive medicine program and trained in emergency medicine at Yale-New Haven Hospital. He holds an MD and MPH from Columbia University and a BA in anthropology from U.C. Berkeley.
Daniel W. Paterson, Chief Operating Officer, On-q-ity
Daniel Paterson is the Chief Operating Officer of On-Q-ity, Inc., an innovative diagnostics company focused on informing and transforming cancer treatment cycle management, improving the quality of life for cancer patients. He leads commercial operations and strategic partnering. Previously, he was the President and CEO of The DNA Repair Company, an oncology-focused molecular diagnostics company that was acquired by On-Q-ity. With 25 years in the healthcare industry, Mr. Paterson garnered extensive oncology experience accompanied by nearly 20 years in management roles in venture-backed healthcare companies. Prior to joining The DNA Repair Company, Paterson worked at IMS Health as Head of Global Strategy for Specialty Market and Patient-Level Data. He joined IMS after it acquired PharMetrics where he was Vice President of Marketing and Corporate Development, and before that, Vice President of Sales, Marketing, and Business Development. While at PharMetrics, Paterson was responsible for developing the strategy, product portfolio, and key partnerships, including playing a key role in the company's eventual sale to IMS. Earlier in his career, Paterson was Vice President of Product Management and Business Development at CareTools, a healthcare information systems company. While there, he oversaw the company's product portfolio and partnership strategy. He was a member of the founding management team for OnCare, an oncology physician practice management company that grew to over $100 million in annual revenue. He was also on the founding management team of Axion, a cancer-focused pharmaceutical and clinical service firm that was rated #4 on the Inc. 500 List of the fastest growing companies in the United States from 1990 to 1995. The company had annual revenues of more than $250 million at the time it was sold to Bristol Myers Squibb. Paterson began his career designing and managing clinical trials in both industry and academic settings, including a nationwide oncology consortium headquartered at the Dana-Farber Cancer Institute. He holds a B.S. in Biology from Boston University and attended Northeastern University's graduate pharmacology program.
Harry Glorikian, Founder and Managing Partner, Scientia Advisors
Harry Glorikian heads Scientia Advisors based on 20 years of experience in the health care and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth. Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Harry has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia's sophisticated framework and proprietary analytic tools.
He writes for trade media, is frequently quoted in periodicals, and is a sought-after speaker who advises media and industry leaders on current trends in life science, health care and business. Harry also serves on many advisory boards. He holds an MBA from Boston University and a BA in Biology from San Francisco State University.Harry is an avid inventor who has several patents and patents pending in the US and abroad.
He writes for trade media, is frequently quoted in periodicals, and is a sought-after speaker who advises media and industry leaders on current trends in life science, health care and business. Harry also serves on many advisory boards. He holds an MBA from Boston University and a BA in Biology from San Francisco State University.Harry is an avid inventor who has several patents and patents pending in the US and abroad.
Corey Braastad, Ph.D., Manager of Operations, Athena Diagnostics
Mr. Braastad is currently Manager of Operations at Athena Diagnostics in Worcester, MA. Athena Diagnostics is a molecular genetics diagnostics company specializing in the diagnosis of rare neurological, renal and endocrine disorders. At Athena he has led teams that (1) develop and launch new diagnostic assays, (2) routinely run diagnostic tests on patient samples, and (3) improve the quality of diagnostic tests by improving result interpretation. He also is leading an effort to implement a quality improvement program at Athena called Practical Process Improvement (PPI). Mr. Braastad received his undergraduate degree from the University of Massachusetts Dartmouth. As a graduate student at Brown University, he was in the Molecular and Cellular Biology and Biochemistry (MC&B) Department working on defining a DNA-damage inducible gene promoter. He then worked as a post-doctoral fellow at the University of Massachusetts Medical School in the Department of Cell Biology to define the cell-cycle regulated histone H4 regulatory elements.
Thomas Neyarapally, Senior Vice President, Corporate Development, Gene Network Sciences
Thomas Neyarapally spearheads and implements the strategic vision for the expansion, protection and monetization of Gene Network Sciences' intellectual property. He was appointed to his current position in 2008. Before joining GNS as Vice President, Corporate Strategy and Intellectual Property in 2006, Neyarapally served as an associate in the New York office of the law firm Frommer, Lawrence & Haug LLP, where he focused on transactional, product development, and litigation matters in the pharmaceutical and biotech industries. Neyarapally previously was an associate in the corporate department at Chadbourne & Parke, LLP, and held the position of analyst at Arthur D. Little. Neyarapally holds a J.D. and an M.B.A. from Cornell University. While attending Cornell's Johnson Graduate School of Management, he served as a partner with BR Ventures, the only student-run venture capital firm in the United States. Neyarapally graduated from the University of Connecticut with a B.S. in chemical engineering.